Activation of systemic, renal tissue and renal vessel levels of PPARγ by chronic pioglitazone treatment has beneficial effects on the endotoxemia-related TNFα/NFκB-mediated acute on chronic renal inflammation in cirrhosis. This evidence concerns the gene NFKB1 and Cirrhosis.